Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor

Trial Profile

Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Anti-MUC1 CAR-T cell therapy (Primary)
  • Indications Colorectal cancer; Gastric cancer; Glioma; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors PersonGen Biomedicine
  • Most Recent Events

    • 11 Jul 2016 Status changed from suspended to recruiting.
    • 21 Jun 2016 Status changed from recruiting to suspended.
    • 03 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top